Why the study?
Myocardial ischemia or hypoxia may contribute to natriuretic peptide release independent of left ventricular function changes, leading the authors to assess this impact and correlate it with cardiac troponins.
Does the severity of myocardial ischemia on regadenoson SPECT MPI correlate with NTproBNP elevation in patients without heart failure or renal dysfunction?
Does the severity of myocardial ischemia on regadenoson SPECT MPI correlate with NTproBNP elevation in patients without heart failure or renal dysfunction?
In patients with reversible myocardial ischemia on SPECT MPI, NTproBNP elevation correlates strongly with troponin T elevation but does not significantly differ across varying severities of ischemia.
Answers are grounded in this paper and cite their sources.
NTproBNP elevation links to troponin but not ischemia severity on SPECT MPI; hypothesis-generating, should not yet change practice.
Background: Natriuretic peptides are released in increased myocardial wall stress, but myocardial ischemia or hypoxia may also contribute to natriuretic peptide release, independent of changes in left ventricular function. Objectives: In our study, we tried to check the impact of myocardial ischemia on the release of natriuretic peptides, and correlated it with cardiac troponins. Methods: We included all the patients with anginal chest pain or equivalents who underwent regadenoson single photon emission computed tomography myocardial perfusion imaging, commonly known as lexiscan, with positive stress results defined as reversible myocardial ischemia, and their corresponding myocardial markers and stress imaging findings were checked. The patients with reduced renal function (defined as glomerular filtration rate <60 ml/min/1.73 m 2 ) and heart failure (with LVEF <40%) were excluded from the study to remove the confounding factors that could contribute to the elevation in natriuretic peptides. Results: In total, 54 patients were studied. The NT-ProBNP levels were above the normal laboratory reference range of 450 ng/ml in 12 (44.4%) patients and >100 ng/ml in 18 (66.7%) patients. The median elevation (25–75 percentiles) of NTproBNP above the laboratory reference range was 1151.5 (645–1618) pg/ml. The combined cardiac troponin I and T (cTnI and cTnT, respectively) concentrations were above the detection level in 30 (55.6%) patients, and the median elevation of cTnI and cTnT was 0.135 (0.035–0.273) ng/ml, and 0.046 (0.021–0.221) ng/ml, respectively. There was a significant strong positive association between the rise of NTproBNP and cTnT elevation ( r = 0.687, P < 0.05), but there was no statistically significant difference in the elevation of NTproBNP across the increasing severity of myocardial ischemic categories on one-way ANOVA ( P > 0.05). Conclusions: The combined cardiac troponin elevation was still higher than NTproBNP elevation. There was no significant difference in the elevation of NTproBNP with increasing severities of myocardial ischemia on a lexiscan, but NTproBNP elevation correlated strongly with cTnT elevation.
No takes yet. Share an insight, caveat, or question.
Mohsin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: